REDUCER Trial (TXA in Urethroplasty)
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexMale
Age18+
SponsorAmjad Alwaal, MD, MSc, FRCSC, FACS
About this trial
This study will test whether tranexamic acid (TXA), a medication used to reduce bleeding, can decrease blood loss in patients having urethroplasty. Participants will be randomly assigned to receive either a single intravenous dose of TXA at the start of anesthesia or standard care without TXA. Researchers will compare hemoglobin change after surgery as well as estimated blood loss and complications.
Eligibility criteria
Qualifiers
Adult patients (≥18 years old)
Undergoing urethroplasty for urethral stricture disease
Ability to provide informed consent
Disqualifiers
Known contraindication to tranexamic acid (TXA)
History of thromboembolic disease (e.g., deep vein thrombosis, pulmonary embolism, stroke)
Known bleeding disorder or coagulopathy
Current use of anticoagulation that cannot be safely held perioperatively
Trial design
Treatments tested in this trial
- Tranexamic Acid
- Urethroplasty
Treatment groups
40 Participants
are divided into 2 treatment groupsSponsors and collaborators
Amjad Alwaal, MD, MSc, FRCSC, FACS
Lead sponsor
Rutgers, The State University of New Jersey
Sponsor institution
Source ClinicalTrials.gov